J&J ramps up its bladder cancer battle
The first approval for TAR-200 is on the horizon, setting up a challenge to Keytruda.
CG gets money before data
CG Oncology and Arrivent pull off US flotations, and both offer speculative investment cases.
The first approval for TAR-200 is on the horizon, setting up a challenge to Keytruda.
CG Oncology and Arrivent pull off US flotations, and both offer speculative investment cases.
